Clinical Trial Update: A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on intermittent oral dosing of ASP1517 in patients with chronic kidney disease on hemodialysis and anemia; study status is complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• ASP1517

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Hemodialysis Chronic Kidney Disease Patients With Anemia | Phase 3 | Status: COMPLETED